Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SNN vs EW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: SNN 3 – 3 EW Matrix Metrics: SNN 4 – 6 EW

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SNN carries a Unified Composite Score of 42.0/100 (HOLD) at $31.01 (13.2x Forward P/E, 14.2% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin).

  • Composite vs. Pillar Nuance: While SNN currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 14.2% operating margin) and revenue trajectory (+10.5% vs. +4.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNN vs EW
SNN NYSE
Smith & Nephew plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$31.01
-0.86% 1D
Market Cap $13.2B
TTM Revenue $6.30B
Forward P/E 13.2x
Beta / 30D Vol 0.28β · 38% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 24.0 Fund 37.0 Flow 50.0 Mom 31.2
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 60
RSI-14: 60.2 · SMA20: $30.68 · SMA50: $28.78
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77

6-Pillar Scorecard Institutional Category Breakdown (SNN 3 – 3 EW)

Columns: Metric · SNN · EW
1. Valuation Multiples SNN
Forward P/E 13.2x 31.6x
Trailing P/E 21.4x 61.5x
PEG Ratio 1.07x 2.33x
EV / Revenue 2.1x 8.8x
2. Growth & Scale EW
Revenue Growth (YoY) +4.6% +10.5%
Earnings Growth (YoY) +5.7% +6.7%
TTM Revenue (USD) $6.30B $6.67B
Market Cap $13.2B $60.8B
3. Profitability & Quality EW
Gross Margin 68.4% 78.0%
Operating Margin 14.2% 28.8%
Net Profit Margin 10.1% 15.3%
Return on Equity (ROE) 11.8% 9.3%
4. Balance Sheet & Cash Flow SNN
Cash Generation (TTM) $1.38B EBITDA $1.42B
Cash Flow Margin 21.9% EBITDA Mgn 21.3%
Net Cash / Leverage $2.43 Book/Sh · 11.8% ROE $2.41B Net Cash
Dividend Yield 2.56% None (0.00%)
5. Options & Positioning EW
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 19.6% (50th %ile) 24.6% (34th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat SNN
OpEx & R&D Intensity 54.2% of Rev ($3.41B) 49.2% of Rev ($3.28B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNN (4) vs EW (6)
Institutional Metric SNN EW Criterion Row Edge
Market Capitalization
Scale
$13.2B $60.8B Larger Scale EW
Trailing P/E Ratio
Valuation
21.4x 61.5x Lower Multiple SNN
Forward P/E Ratio
Valuation
13.2x 31.6x Lower Multiple SNN
Revenue Growth (YoY)
Growth
+4.6% +10.5% Higher Growth EW
Operating Margin (TTM)
Profitability
14.2% 28.8% Higher Margin EW
Net Profit Margin
Profitability
10.1% 15.3% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
11.8% 9.3% Higher ROE SNN
52-Week Range Position
Momentum
45% ($26–$37) 96% ($75–$108) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.28β · 38% Vol 0.44β · 24% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite SNN
Trailing 12M Revenue (USD)
Operating Scale
$6.30B $6.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.4% 78.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.07x PEG · 2.1x EV/Rev 2.33x PEG · 8.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.38B EBITDA ($2.43 Book/Sh · 11.8% ROE) $1.42B ($2.41B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +16.45 pp
SNN: +6.71% · EW: +23.16%
3M Horizon EW +14.51 pp
SNN: +2.72% · EW: +17.23%
6M Horizon EW +27.11 pp
SNN: +2.34% · EW: +29.45%
1Y Horizon EW +29.8 pp
SNN: -5.94% · EW: +23.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNN vs EW. Trailing 12-month operating profitability (SNN 14.2% vs EW 28.8%) and valuation multiples (SNN 13.2x vs EW 31.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SNN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.30B
Gross Margin68.4%
Op. Margin14.2%
ROE / Fwd P/E11.8% · 13.2x
EW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.67B
Gross Margin78.0%
Op. Margin28.8%
ROE / Fwd P/E9.3% · 31.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 19.6%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $13.2B market capitalization and 14.2% operating margin.
OpEx & R&D Reinvestment 54.2% of Rev ($3.41B)
90D Engineering Disclosures 0 Published
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published

Investor FAQ SNN vs EW Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SNN carries a Unified Composite Score of 42.0/100 (HOLD) at $31.01 (13.2x Forward P/E, 14.2% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin). Composite vs. Pillar Nuance: While SNN currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 14.2% operating margin) and revenue trajectory (+10.5% vs. +4.6% YoY).

EW leads the Growth & Scale pillar: SNN posts +4.6% YoY revenue growth and +5.7% YoY earnings growth on $6.30B TTM revenue (68.4% gross margin, 14.2% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). On trailing 12-month operating scale, SNN generates $6.30B in USD-normalized revenue versus $6.67B for EW. In operating R&D and SG&A reinvestment, SNN deploys 54.2% of Rev ($3.41B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.

SNN screens cheaper on headline valuation multiples. SNN trades at 13.2x Forward P/E, 21.4x Trailing P/E, 1.07x PEG, and 2.1x EV/Revenue (21.9% EBITDA margin), whereas EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNN (11.8% ROE) versus EW (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SNN carries 19.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 38% Vol realized risk). By comparison, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.